Dendritic Cell-Based Immunotherapy

REFERENCES

• C. Ardavin, S. Amigorena, and C. Reis e Sousa, Dendritic cells: Immunobiology and cancer immunotherapy, Immunity, 20(1): 17–23, 2004. [CSA]
   PubMedGoogle Scholar
• G. Schuler, B. Schuler-Thurner, and R.M. Steinman, The use of dendritic cells in cancer immunotherapy, Curr. Opin. Immunol., 15(2): 138–147, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.A. Morse and H.K. Lyerly, Clinical applications of dendritic cell vaccines, Curr. Opin. Mol. Ther., 2(1): 20–28, 2000. [CSA]
   Google Scholar
• Y.J. Liu, H. Kanzler, V. Soumelis, and M. Gilliet, Dendritic cell lineage, plasticity and cross-regulation, Nat. Immunol., 2(7): 585–589, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Moser and K.M. Murphy, Dendritic cell regulation of TH1-TH2 development, Nat. Immunol., 1(3): 199–205, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Schnurr, Q. Chen, A. Shin, , et al., Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery, Blood, 105(6): 2465–2472, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Lanzavecchia and F. Sallusto, The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics, Curr. Opin. Immunol., 13(3): 291–298, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.B. Fearnley, L.F. Whyte, S.A. Carnoutsos, A.H. Cook, and D.N. Hart, Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation, Blood, 93(2): 728–736, 1999. [CSA]
   Google Scholar
• F.J. Hsu, C. Benike, F. Fagnoni, , et al., Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nat. Med., 2(1): 52–58, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V.L. Reichardt, C.Y. Okada, A. Liso, , et al., Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—A feasibility study, Blood, 93(7): 2411–2419, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• E.J. Small, P. Fratesi, D.M. Reese, , et al., Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells, J. Clin. Oncol., 18(23): 3894–3903, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• T.K. Hoffmann, J. Muller-Berghaus, R.L. Ferris, , et al., Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck, Clin. Cancer Res., 8(6): 1787–1793, 2002. [CSA]
   Web of Science ®Google Scholar
• S. Satthaporn, A. Robins, W. Vassanasiri, , et al., Dendritic cells are dysfunctional in patients with operable breast cancer, Cancer Immunol. Immunother., 53(6): 510–518, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.D. Brown, B. Pope, A. Murray, , et al., Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10, Blood, 98(10): 2992–2998, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Ratta, F. Fagnoni, A. Curti, , et al., Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6, Blood, 100(1): 230–237, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.M. Timmerman, D.K. Czerwinski, T.A. Davis, , et al., Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients, Blood, 99(5): 1517–1526, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.J. Small, P.F. Schellhammer, C.S. Higano, , et al., Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer, J. Clin. Oncol., 24(19): 3089–3094, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Sallusto and A. Lanzavecchia, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha, J. Exp. Med., 179(4): 1109–1118, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Cao, V. Verge, C. Baron, , et al., In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy, J. Hematother. Stem Cell. Res., 9(2): 183–194, 2000. [CSA], [CROSSREF]
   Google Scholar
• M.A. Morse, H.K. Lyerly, and Y. Li, The role of IL-13 in the generation of dendritic cells in vitro, J. Immunother., 22(6): 506–513, 1999. [CSA], [CROSSREF]
   Google Scholar
• K. Tarte, G. Fiol, J.F. Rossi, and B. Klein, Extensive characterization of dendritic cells generated in serum-free conditions: Regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro, Leukemia, 14(12): 2182–2192, 2000. [CSA], [CROSSREF]
   Google Scholar
• D.I. Gabrilovich, S. Nadaf, J. Corak, J.A. Berzofsky, and D.P. Carbone, Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors, Cell. Immunol., 170(1): 111–119, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Banchereau and A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer, Nat. Rev. Immunol., 5(4): 296–306, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B. Chen, P. Stiff, G. Sloan, , et al., Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli, Clin. Immunol., 98(2): 280–292, 2001. [CSA], [CROSSREF]
   Google Scholar
• A. Curti, M. Fogli, M. Ratta, , et al., Dendritic cell differentiation from hematopoietic CD34+ progenitor cells, J. Biol. Regul. Homeost. Agents, 15(1): 49–52, 2001. [CSA]
   Google Scholar
• J. Banchereau, A.K. Palucka, M. Dhodapkar, , et al., Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res., 61(17): 6451–6458, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Di Nicola, C. Carlo-Stella, R. Mortarini, , et al., Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma, Clin. Cancer Res., 10(16): 5381–5390, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Mackensen, B. Herbst, J.L. Chen, , et al., Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells, Int. J. Cancer, 86(3): 385–392, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Titzer, O. Christensen, O. Manzke, , et al., Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects, Br. J. Haematol., 108(4): 805–816, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Mortarini, A. Anichini, M. Di Nicola, , et al., Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27–35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors, Cancer Res., 57(24): 5534–5541, 1997. [CSA]
   Google Scholar
• G. Ferlazzo, J. Klein, X. Paliard, W.Z. Wei, and A. Galy, Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells, J. Immunother., 23(1): 48–58, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.F. Claxton, J. McMannis, R. Champlin, and A. Choudhury, Therapeutic potential of leukemia-derived dendritic cells: Preclinical and clinical progress, Crit. Rev. Immunol., 21(1–3): 147–155, 2001. [CSA]
   Google Scholar
• J. Westermann, J. Kopp, I. Korner, , et al., Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia, Bone Marrow Transplant., 25(Suppl 2): S46–S49, 2000. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• R. Syme, T. Bryan, P. Duggan, , et al., Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro, Stem Cells Dev., 13(2): 211–221, 2004. [CSA], [CROSSREF]
   Google Scholar
• A. Cignetti, E. Bryant, B. Allione, , et al., CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells, Blood, 94(6): 2048–2055, 1999. [CSA]
   Google Scholar
• M. Narita, M. Takahashi, A. Liu, , et al., Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia, Exp. Hematol., 29(6): 709–719, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.B. Dietz, P.A. Bulur, M.R. Erickson, , et al., Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells, J. Hematother. Stem Cell Res., 9(1): 95–101, 2000. [CSA], [CROSSREF]
   Google Scholar
• H. Roddie, M. Klammer, C. Thomas, , et al., Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia, Br. J. Haematol., 133(2): 152–157, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K. Eisendle, D. Wolf, G. Gastl, and B. Kircher-Eibl, Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features, Leuk. Lymphoma, 46(5): 663–670, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• Y. Suen, S.M. Lee, F. Aono, , et al., Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC, Cytotherapy, 3(5): 365–375, 2001. [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• M. Elias, J. van Zanten, G.A. Hospers, , et al., Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy, J. Clin. Apher., 20(4): 197–207, 2005. [CSA], [CROSSREF]
   Google Scholar
• E.C. Wong, S.M. Lee, K. Hines, , et al., Development of a closed-system process for clinical-scale generation of DCs: Evaluation of two monocyte-enrichment methods and two culture containers, Cytotherapy, 4(1): 65–76, 2002. [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• B. Goxe, N. Latour, M. Chokri, J.P. Abastado, and M. Salcedo, Simplified method to generate large quantities of dendritic cells suitable for clinical applications, Immunol. Invest., 29(3): 319–336, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• B. Barrou, G. Benoit, M. Ouldkaci, , et al., Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA, Cancer Immunol. Immunother., 53(5): 453–460, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.A. Brott, R.J. Maher, C.R. Parrish, R.J. Richardson, and A.K. Smith, Flow cytometric characterization of perfused human bone marrow cultures: Identification of the major cell lineages and correlation with the CFU-GM assay, Cytometry A, 53(1): 22–27, 2003. [CSA]
   Google Scholar
• P.A. Burch, J.K. Breen, J.C. Buckner, , et al., Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer, Clin. Cancer Res., 6(6): 2175–2182, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Mackensen, R. Drager, M. Schlesier, R. Mertelsmann, and A. Lindemann, Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells, Cancer Immunol. Immunother., 49(3): 152–156, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.D. Roth, B.J. Gitlitz, S.M. Kiertscher, , et al., Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients, Cancer Res., 60(7): 1934–1941, 2000. [CSA]
   Google Scholar
• S.M. Kiertscher, B.J. Gitlitz, R.A. Figlin, and M.D. Roth, Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients, Int. J. Cancer, 107(2): 256–261, 2003. [CSA], [CROSSREF]
   Google Scholar
• J.E. Janik, L.L. Miller, W.C. Kopp, , et al., Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients, Clin. Immunol., 93(3): 209–221, 1999. [CSA], [CROSSREF]
   Google Scholar
• E. Maraskovsky, K. Brasel, M. Teepe, , et al., Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified, J. Exp. Med., 184(5): 1953–1962, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• H.J. McKenna, Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells, Curr. Opin. Hematol., 8(3): 149–154, 2001. [CSA]
   Google Scholar
• E. Maraskovsky, E. Daro, E. Roux, , et al., In vivo generation of human dendritic cell subsets by Flt3 ligand, Blood, 96(3): 878–884, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• B. Pulendran, J. Banchereau, S. Burkeholder, , et al., Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo, J. Immunol., 165(1): 566–572, 2000. [CSA]
   Google Scholar
• C.E. Marroquin, J.A. Westwood, R. Lapointe, , et al., Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells, J. Immunother., 25(3): 278–288, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Merad, T. Sugie, E.G. Engleman, and L. Fong, In vivo manipulation of dendritic cells to induce therapeutic immunity, Blood, 99(5): 1676–1682, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Arpinati, C.L. Green, S. Heimfeld, J.E. Heuser, and C. Anasetti, Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells, Blood, 95(8): 2484–2490, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Vuckovic, M. Kim, D. Khalil, , et al., Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression, Blood, 101(6): 2314–2317, 2003. [CSA], [CROSSREF]
   Google Scholar
• S. Ferrari, B. Rovati, C. Porta, , et al., Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor, Cancer Immunol. Immunother., 52(6): 359–366, 2003. [CSA]
   Google Scholar
• S. Lonial, M. Hicks, H. Rosenthal, , et al., A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products, Biol. Blood Marrow Transplant., 10(12): 848–857, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• P.R. Streeter, N.I. Minster, L.E. Kahn, , et al., Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor, Exp. Hematol., 29(1): 41–50, 2001. [CSA], [CROSSREF]
   Google Scholar
• P. Bjorck, W.R. Lie, S.L. Woulfe, , et al., Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model, Int. J. Cancer, 100(5): 586–591, 2002. [CSA], [CROSSREF]
   Google Scholar
• V. Pullarkat, P.P. Lee, R. Scotland, , et al., A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma, Clin. Cancer Res., 9(4): 1301–1312, 2003. [CSA]
   Google Scholar
• Y. Zhang, H. Yoneyama, Y. Wang, , et al., Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice, J. Natl. Cancer Inst., 96(3): 201–209, 2004. [CSA]
   PubMedGoogle Scholar
• P. Lissoni, A. Bonfanti, V. Bordin, , et al., Malignancy: Changes in circulating immature and mature dendritic cells during IL-2 cancer immunotherapy and their relation with lymphocyte increase and clinical response, Hematology, 5(2): 117–125, 2000. [CSA]
   PubMedGoogle Scholar
• S. Morel, F. Levy, O. Burlet-Schiltz, , et al., Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells, Immunity, 12(1): 107–117, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.M. Zinkernagel, On cross-priming of MHC class I-specific CTL: Rule or exception? Eur. J. Immunol., 32(9): 2385–2392, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.C. Wolkers, N. Brouwenstijn, A.H. Bakker, M. Toebes, and T.N. Schumacher, Antigen bias in T cell cross-priming, Science, 304(5675): 1314–1317, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y. Li, M. Bendandi, Y. Deng, , et al., Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells, Blood, 96(8): 2828–2833, 2000. [CSA]
   Google Scholar
• L. Bonifaz, D. Bonnyay, K. Mahnke, , et al., Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance, J. Exp. Med., 196(12): 1627–1638, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K.M. Dhodapkar, J. Krasovsky, B. Williamson, and M.V. Dhodapkar, Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells, J. Exp. Med., 195(1): 125–133, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Smithers, K. O'Connell, S. MacFadyen, , et al., Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen, Cancer Immunol. Immunother., 52(1): 41–52, 2003. [CSA]
   Google Scholar
• J.S. Yu, C.J. Wheeler, P.M. Zeltzer, , et al., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, Cancer Res., 61(3): 842–847, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• B. Thurner, I. Haendle, C. Roder, , et al., Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J. Exp. Med., 190(11): 1669–1678, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Fong, Y. Hou, A. Rivas, , et al., Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 98(15): 8809–8814, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T.N. Bullock, T.A. Colella, and V.H. Engelhard, The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice, J. Immunol., 164(5): 2354–2361, 2000. [CSA]
   Google Scholar
• Y. Waeckerle-Men, E. Scandella, E. Uetz-Von Allmen, , et al., Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy, J. Immunol. Methods, 287(1–2): 109–124, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Boczkowski, S.K. Nair, D. Snyder, and E. Gilboa, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J. Exp. Med., 184(2): 465–472, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.A. Mitchell and S.K. Nair, RNA transfected dendritic cells as cancer vaccines, Curr. Opin. Mol. Ther., 2(2): 176–181, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• V.F. Van Tendeloo, P. Ponsaerts, F. Lardon, , et al., Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells, Blood, 98(1): 49–56, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I. Strobel, S. Berchtold, A. Gotze, , et al., Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes, Gene Ther., 7(23): 2028–2035, 2000. [CSA], [CROSSREF]
   Google Scholar
• S.K. Nair, D. Boczkowski, M. Morse, , et al., Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA, Nat. Biotechnol., 16(4): 364–369, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Heiser, M.A. Maurice, D.R. Yancey, , et al., Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA, J. Immunol., 166(5): 2953–2960, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Boczkowski, S.K. Nair, J.H. Nam, H.K. Lyerly, and E. Gilboa, Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells, Cancer Res., 60(4): 1028–1034, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Nencioni, M.R. Muller, F. Grunebach, , et al., Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer, Cancer Gene Ther., 10(3): 209–214, 2003. [CSA], [CROSSREF]
   Google Scholar
• M.R. Muller, F. Grunebach, A. Nencioni, and P. Brossart, Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes, J. Immunol., 170(12): 5892–5896, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• C. Milazzo, V.L. Reichardt, M.R. Muller, F. Grunebach, and P. Brossart, Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA, Blood, 101(3): 977–982, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Bubenik, Genetically engineered dendritic cell-based cancer vaccines (review) Int. J. Oncol., 18(3): 475–478, 2001. [CSA]
   Google Scholar
• K.M. Ardeshna, A.R. Pizzey, N.S. Thomas, S. Orr, D.C. Linch, S. Devereux, monocyte-derived dendritric cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol., 108(4): 817–824, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Dyall, J.B. Latouche, S. Schnell, and M. Sadelain, Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes, Blood, 97(1): 114–121, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Firat, V. Zennou, F. Garcia-Pons, , et al., Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy, J. Gene Med., 4(1): 38–45, 2002. [CSA], [CROSSREF]
   Google Scholar
• G. Lizee, M.I. Gonzales, and S.L. Topalian, Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells, Hum. Gene Ther., 15(4): 393–404, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Dull, R. Zufferey, M. Kelly, , et al., A third-generation lentivirus vector with a conditional packaging system, J. Virol., 72(11): 8463–8471, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• Y. He, J. Zhang, Z. Mi, P. Robbins, and L.D. Falo, Jr., Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity, J. Immunol., 174(6): 3808–3817, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Di Nicola, C. Carlo-Stella, M. Milanesi, , et al., Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex, Br. J. Haematol., 111(1): 344–350, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Amalfitano, M.A. Hauser, H. Hu, , et al., Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted, J. Virol., 72(2): 926–933, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Rea, M.J. Havenga, M. van Den Assem, , et al., Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells, J. Immunol., 166(8): 5236–5244, 2001. [CSA]
   Google Scholar
• S. Worgall, A. Busch, M. Rivara, , et al., Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses, J. Virol., 78(5): 2572–2580, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Brown, Y. Zhang, S. Dermine, , et al., Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity, Gene Ther., 7(19): 1680–1689, 2000. [CSA], [CROSSREF]
   Google Scholar
• C.J. Kim, J. Cormier, M. Roden, , et al., Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity, Ann. Surg. Oncol., 5(1): 64–76, 1998. [CSA], [CROSSREF]
   Google Scholar
• M. Zhu, H. Terasawa, J. Gulley, , et al., Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells, Cancer Res., 61(9): 3725–3734, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• K.Y. Tsang, C. Palena, J. Yokokawa, , et al., Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules, Clin. Cancer Res., 11(4): 1597–1607, 2005. [CSA]
   Google Scholar
• I.J. Caley, M.R. Betts, D.M. Irlbeck, , et al., Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector, J. Virol., 71(4): 3031–3038, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• P. Pushko, M. Parker, G.V. Ludwig, , et al., Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo, Virology, 239(2): 389–401, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T.P. Moran, M. Collier, K.P. McKinnon, , et al., A novel viral system for generating antigen-specific T cells, J. Immunol., 175(5): 3431–3438, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• Z. Chen, T. Moyana, A. Saxena, , et al., Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells, Int. J. Cancer, 93(4): 539–548, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Shaif-Muthana, C. McIntyre, K. Sisley, I. Rennie, and A. Murray, Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells, Cancer Res., 60(22): 6441–6447, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Ferlazzo, C. Semino, G.M. Spaggiari, , et al., Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates, Int. Immunol., 12(12): 1741–1747, 2000. [CSA], [CROSSREF]
   Google Scholar
• J. Galea-Lauri, J.W. Wells, D. Darling, P. Harrison, and F. Farzaneh, Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination, Cancer Immunol. Immunother., 53(11): 963–977, 2004. [CSA]
   Google Scholar
• T. Kurokawa, M. Oelke, and A. Mackensen, Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells, Int. J. Cancer, 91(6): 749–756, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L.A. Lambert, G.R. Gibson, M. Maloney, and R.J. Barth, Jr., Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens, J. Immunother., 24(3): 232–236, 2001. [CSA], [CROSSREF]
   Google Scholar
• J.S. Yu, G. Liu, H. Ying, , et al., Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma, Cancer Res., 64(14): 4973–4979, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• W.C. Lee, H.C. Wang, C.F. Hung, , et al., Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial, J. Immunother., 28(5): 496–504, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.E. Chang, B.G. Redman, J.R. Whitfield, , et al., A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer, Clin. Cancer Res., 8(4): 1021–1032, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, , et al., Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration, Cancer Res., 63(23): 8466–8475, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• J. Gong, N. Nikrui, D. Chen, , et al., Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity, J. Immunol., 165(3): 1705–1711, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Koido, M. Ohana, C. Liu, , et al., Dendritic cells fused with human cancer cells: Morphology, antigen expression, and T cell stimulation, Clin. Immunol., 113(3): 261–269, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Koido, E. Hara, S. Homma, , et al., Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells, Clin. Cancer Res., 11(21): 7891–7900, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.R. Parkhurst, C. DePan, J.P. Riley, S.A. Rosenberg, and S. Shu, Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules, J. Immunol., 170(10): 5317–5325, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• T.H. Scott-Taylor, R. Pettengell, I. Clarke, , et al., Human tumour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines, Biochim. Biophys. Acta, 1500(3): 265–279, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Marten, S. Renoth, T. Heinicke, , et al., Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma, Hum. Gene Ther., 14(5): 483–494, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Kikuchi, Y. Akasaki, M. Irie, , et al., Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells, Cancer Immunol. Immunother., 50(7): 337–344, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Schnurr, P. Galambos, C. Scholz, , et al., Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines, Cancer Res., 61(17): 6445–6450, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Toungouz, M. Libin, F. Bulte, , et al., Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors, J. Leukoc. Biol., 69(6): 937–943, 2001. [CSA]
   Google Scholar
• A.L. Millard, D. Ittelet, F. Schooneman, and J. Bernard, Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines, Vaccine, 21(9–10): 869–876, 2003. [CSA], [CROSSREF]
   Google Scholar
• P. Brossart, K.S. Heinrich, G. Stuhler, , et al., Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies, Blood, 93(12): 4309–4317, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• J. Wierecky, M.R. Muller, S. Wirths, , et al., Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients, Cancer Res., 66(11): 5910–5918, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I.J. de Vries, W.J. Lesterhuis, N.M. Scharenborg, , et al., Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients, Clin. Cancer Res., 9(14): 5091–5100, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• H. Jonuleit, A. Giesecke-Tuettenberg, T. Tuting, , et al., A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection, Int. J. Cancer, 93(2): 243–251, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.V. Dhodapkar, R.M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj, Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells, J. Exp. Med., 193(2): 233–238, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. McIlroy and M. Gregoire, Optimizing dendritic cell-based anticancer immunotherapy: Maturation state does have clinical impact, Cancer Immunol. Immunother., 52(10): 583–591, 2003. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• P.J. Mosca, A.C. Hobeika, T.M. Clay, , et al., A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment, Blood, 96(10): 3499–3504, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• B.J. Czerniecki, P.A. Cohen, M. Faries, , et al., Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines, Crit. Rev. Immunol., 21(1–3): 157–178, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• I.J. De Vries, D.J. Krooshoop, N.M. Scharenborg, , et al., Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state, Cancer Res., 63(1): 12–17, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• B. Schuler-Thurner, E.S. Schultz, T.G. Berger, , et al., Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells, J. Exp. Med., 195(10): 1279–1288, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Jonuleit, U. Kuhn, G. Muller, , et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions, Eur. J. Immunol., 27(12): 3135–3142, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• P. Kalinski, J.H. Schuitemaker, C.M. Hilkens, and M.L. Kapsenberg, Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+ CD83+ dendritic cells: The levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation, J. Immunol., 161(6): 2804–2809, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• T. Luft, M. Jefford, P. Luetjens, , et al., Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: Prostaglandin E(2) regulates the migratory capacity of specific DC subsets, Blood, 100(4): 1362–1372, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E. Scandella, Y. Men, S. Gillessen, R. Forster, and M. Groettrup, Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells, Blood, 100(4): 1354–1361, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Luft, K.C. Pang, E. Thomas, , et al., Type I IFNs enhance the terminal differentiation of dendritic cells, J. Immunol., 161(4): 1947–1953, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• S.M. Santini, C. Lapenta, M. Logozzi, , et al., Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice, J. Exp. Med., 191(10): 1777–1788, 2000. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• C. Pasare and R. Medzhitov, Toll-like receptors: Linking innate and adaptive immunity, Microbes Infect., 6(15): 1382–1387, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.P. Murphy, B.A. Tjoa, S.J. Simmons, , et al., Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients, Prostate, 43(1): 59–62, 2000. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• A. Ribas, L.H. Butterfield, B. Hu, , et al., Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice, Cancer Res., 60(8): 2218–2224, 2000. [CSA]
   Google Scholar
• J.S. Serody, E.J. Collins, R.M. Tisch, J.J. Kuhns, and J.A. Frelinger, T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery, J. Immunol., 164(9): 4961–4967, 2000. [CSA]
   Google Scholar
• M.V. Dhodapkar, R.M. Steinman, M. Sapp, , et al., Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells, J. Clin. Invest., 104(2): 173–180, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• M.A. Morse, T.M. Clay, A.C. Hobeika, , et al., Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules, Clin. Cancer Res., 11(8): 3017–3024, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.A. Morse, R.E. Coleman, G. Akabani, , et al., Migration of human dendritic cells after injection in patients with metastatic malignancies, Cancer Res., 59(1): 56–58, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Mackensen, T. Krause, U. Blum, , et al., Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells, Cancer Immunol. Immunother., 48(2–3): 118–122, 1999. [CSA], [CROSSREF]
   Google Scholar
• L.A. Lambert, G.R. Gibson, M. Maloney, , et al., Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity, Cancer Res., 61(2): 641–646, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• D.W. Mullins, S.L. Sheasley, R.M. Ream, , et al., Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control, J. Exp. Med., 198(7): 1023–1034, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Fong, D. Brockstedt, C. Benike, L. Wu, and E.G. Engleman, Dendritic cells injected via different routes induce immunity in cancer patients, J. Immunol., 166(6): 4254–4259, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• K.A. Candido, K. Shimizu, J.C. McLaughlin, , et al., Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents, Cancer Res., 61(1): 228–236, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• P.L. Triozzi, R. Khurram, W.A. Aldrich, , et al., Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer, Cancer, 89(12): 2646–2654, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• K.H. Chi, S.J. Liu, C.P. Li, , et al., Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma, J. Immunother., 28(2): 129–135, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.Y. Nikitina and D.I. Gabrilovich, Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer, Int. J. Cancer, 94(6): 825–833, 2001. [CSA], [CROSSREF]
   Google Scholar
• F. Tanaka, H. Yamaguchi, M. Ohta, , et al., Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo, Int. J. Cancer, 101(3): 265–269, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Saji, W. Song, K. Furumoto, H. Kato, and E.G. Engleman, Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy, Clin. Cancer Res., 12(8): 2568–2574, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.D. Geiger, R.J. Hutchinson, L.F. Hohenkirk, , et al., Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression, Cancer Res., 61(23): 8513–8519, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Stift, J. Friedl, P. Dubsky, , et al., Dendritic cell-based vaccination in solid cancer, J. Clin. Oncol., 21(1): 135–142, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• P. Hersey, S.W. Menzies, G.M. Halliday, , et al., Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma, Cancer Immunol. Immunother., 53(2): 125–134, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I.J. de Vries, M.R. Bernsen, W.J. Lesterhuis, , et al., Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome, J. Clin. Oncol., 23(24): 5779–5787, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L.H. Butterfield, A. Ribas, V.B. Dissette, , et al., Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma, Clin. Cancer Res., 9(3): 998–1008, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• P. Therasse, S.G. Arbuck, E.A. Eisenhauer, , et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 92(3): 205–216, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L.D. Cranmer, K.T. Trevor, and E.M. Hersh, Clinical applications of dendritic cell vaccination in the treatment of cancer, Cancer Immunol. Immunother., 53(4): 275–306, 2004. [CSA], [CROSSREF]
   Google Scholar
• U. Trefzer, G. Herberth, K. Wohlan, , et al., Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results, Vaccine, 23(17–18): 2367–2373, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Tuettenberg, C. Becker, E. Huter, , et al., Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients, Int. J. Cancer, 118(10): 2617–2627, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V.L. Reichardt, C. Milazzo, W. Brugger, , et al., Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells, Haematologica, 88(10): 1139–1149, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Bendandi, M. Rodriguez-Calvillo, S. Inoges, , et al., Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation, Leuk. Lymphoma, 47(1): 29–37, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.A. Morse, S.K. Nair, P.J. Mosca, , et al., Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA, Cancer Invest., 21(3): 341–349, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Heiser, D. Coleman, J. Dannull, , et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, J. Clin. Invest., 109(3): 409–417, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z. Su, J. Dannull, B.K. Yang, , et al., Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer, J. Immunol., 174(6): 3798–3807, 2005. [CSA]
   PubMedGoogle Scholar
• S. Fuessel, A. Meye, M. Schmitz, , et al., Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial, Prostate, 66(8): 811–821, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Holtl, R. Ramoner, C. Zelle-Rieser, , et al., Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide, Cancer Immunol. Immunother., 54(7): 663–670, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Chang, S. Syrjanen, and K. Syrjanen, Implications of the p53 tumor-suppressor gene in clinical oncology, J. Clin. Oncol., 13(4): 1009–1022, 1995. [CSA]
   Google Scholar
• I.M. Svane, A.E. Pedersen, H.E. Johnsen, , et al., Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: Report from a phase I study, Cancer Immunol. Immunother., 53(7): 633–641, 2004. [CSA], [CROSSREF]
   Google Scholar
• L.M. Liau, R.M. Prins, S.M. Kiertscher, , et al., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, Clin. Cancer Res., 11(15): 5515–5525, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.Q. Phan, J.C. Yang, R.M. Sherry, , et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci. U.S.A., 100(14): 8372–8377, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Dannull, Z. Su, D. Rizzieri, , et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells, J. Clin. Invest., 115(12): 3623–3633, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar